BiotechTube
Discovery Life Sciences

Discovery Life Sciences

Huntsville, United States· Est.
dls.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $150M

Overview

Discovery Life Sciences operates as a critical enabler in the precision medicine ecosystem, providing the foundational biological materials and analytical services needed for drug and diagnostic development. The company has built a vertically integrated platform combining the world's largest commercial biospecimen inventory with advanced genomics, proteomics, molecular pathology, and cell biology service laboratories. Its strategic acquisitions, such as AllCells and BioServe, have expanded its capabilities into apheresis-derived starting materials and large-scale genomic services, positioning it as a single strategic partner for large-scale clinical trials. By bridging the gap between sample acquisition and data generation, Discovery reduces development timelines for its clients across biopharma, diagnostics, and cell & gene therapy.

OncologyAutoimmune DiseasesLiver Diseases

Technology Platform

Integrated ecosystem combining the world's largest commercial biospecimen inventory (Discovery BioStore) with multi-omic specialty lab services (Genomics, Proteomics, Molecular Pathology, Cell Biology), apheresis-derived cell therapy starting materials (via AllCells), and hepatic science/ADME platforms (Gentest).

Funding History

1
Total raised:$150M
Private Equity$150M

Opportunities

The rapid growth of cell and gene therapy creates massive demand for its apheresis-derived starting materials and characterization services.
The industry-wide shift towards biomarker-driven development and complex clinical trials fuels need for its integrated, large-scale biospecimen and central lab service model.
Partnerships with AI companies like Mindpeak and PathAI allow it to enhance the data value extracted from its physical sample portfolio.

Risk Factors

Revenue is tied to biopharma R&D spending, which is cyclical and sensitive to macroeconomic and funding downturns.
Operating a global human biospecimen supply chain involves significant regulatory (GDPR, HIPAA), ethical, and logistical risks.
The market is competitive, requiring constant innovation to maintain its value proposition against large CROs and niche specialists.

Competitive Landscape

Discovery competes with large, full-service Contract Research Organizations (CROs) like LabCorp's Covance and IQVIA's Q² Solutions that offer central lab services, as well as specialized biospecimen providers (e.g., Precision for Medicine, Indivumed) and standalone genomic service labs. Its key differentiation is the vertical integration of massive specimen sourcing with deep, in-house multi-omic analysis and a dominant position in apheresis for cell therapy.

More companies in Diagnostics & Precision Medicine →More companies in United States →